| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA718: Ixekizumab for treating axial spondyloarthritis |
|
Medicine details |
|
| Medicine name | ixekizumab (Taltz®) |
| Formulation | 80 mg solution for injection |
| Reference number | 3143 |
| Indication | Treatment of adult patients with active ankylosing spondylitis (radiographic axial spondyloarthritis) who have responded inadequately to conventional therapy, or non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs) |
| Company | Eli Lilly & Co Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 10/09/2020 |
| NICE guidance | |